google-site-verification=iUxCUgpoCQNGCS2CQuHi1L8aGqyfkykwcZUHtbSwrts
top of page
< Back

Nicotinamide Riboside Improves Stemness of Human Adipose-Derived Stem Cells and Inhibits Terminal Adipocyte Differentiation

Pharmaceuticals

August 10, 2023

Chinnapaka, Somaiah

Summary

NR administration improves the stemness-related genes expression in ASCs and mitigates their propensity for adipocyte differentiation. These results suggest that NR treatment holds promise as a potential strategy to rejuvenate the stemness of aged adipose-derived stem cells.

https://www.mdpi.com/1424-8247/16/8/1134

Follow Us!

  • Instagram
  • Facebook
  • Twitter
Screen Shot 2022-12-28 at 9.59.55 AM.png
Photo of the site's author, Shelly Albaum - 148x200

I am Shelly Albaum, and this is my personal website and blog. All the opinions presented here are my own. Nobody writes here but me. You can read more about me here. Cookies are not required to use this website. Read more about that here. 

​

Original work © 2022 by Right of Assembly

No claim to research or any work of others

IMPORTANT DISCLOSURES

1. Health Supplements Are Not Medicines. Health Supplements that raise NAD levels, like nicotinamide riboside or other NAD precursors, are not intended to diagnose, treat, cure, or prevent any disease.

​

2. No Medical Advice. I am a lawyer and a journalist, not a doctor, and I offer no medical advice. But I do follow the science, and I can bring to your attention some interesting studies. You can read more about me here. And check with your physician -- your physician can look at this research, too.

​

3. Commercial Affiliations. I am a ChromaDex shareholder, and a marketing affiliate for Amazon and Rakuten. As a result, I will sometimes mention or recommend products that I endorse, like Tru Niagen, which I take every day. I may earn a small commission from qualifying purchases if you were referred directly from this site and completed a purchase. [Thank you!] You can read more about our advertising, privacy, and data collection policies here. 

bottom of page